Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Advances in Therapy
|
October 6, 2023
Long-Term Outcomes of Eladocagene Exuparvovec Compared with Standard of Care in Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Modelling Study
Claire L Simons, Wuh-Liang Hwu, Rongrong Zhang, et al.
Pharmacoeconomics
|
May 21, 2024
Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective
Takao Takeshima, Fumihiko Sakai, Xinyu Wang, et al.
Pharmacoeconomics
|
June 15, 2023
Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migraine Patients
Xinyu Wang, Kentaro Yamato, Yoshitsugu Kojima, et al.
Journal of Medical Economics
|
March 4, 2024
A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands
Martijn J H G Simons, Peter M Machielsen, Jelle A Spoorendonk, et al.
BMC Cancer
|
May 2, 2021
Whole genome sequencing in oncology: using scenario drafting to explore future developments
Michiel van de Ven, Martijn J H G Simons, Hendrik Koffijberg, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 16, 2022
Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer
Martijn J H G Simons, Carin A Uyl-de Groot, Valesca P Retèl, et al.
Pharmacoeconomics
|
January 9, 2024
Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy
Zakile A Mfumbilwa, Martijn J H G Simons, Bram Ramaekers, et al.
Scientific Reports
|
February 9, 2023
Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
Zakile A Mfumbilwa, Janneke A Wilschut, Martijn J H G Simons, et al.
Pharmacoeconomics
|
August 18, 2021
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
Martijn J H G Simons, Valesca P Retèl, Bram L T Ramaekers, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Advances in Therapy
|
October 6, 2023
Long-Term Outcomes of Eladocagene Exuparvovec Compared with Standard of Care in Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Modelling Study
Claire L Simons, Wuh-Liang Hwu, Rongrong Zhang, et al.
Pharmacoeconomics
|
May 21, 2024
Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective
Takao Takeshima, Fumihiko Sakai, Xinyu Wang, et al.
Pharmacoeconomics
|
June 15, 2023
Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migraine Patients
Xinyu Wang, Kentaro Yamato, Yoshitsugu Kojima, et al.
Journal of Medical Economics
|
March 4, 2024
A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands
Martijn J H G Simons, Peter M Machielsen, Jelle A Spoorendonk, et al.
BMC Cancer
|
May 2, 2021
Whole genome sequencing in oncology: using scenario drafting to explore future developments
Michiel van de Ven, Martijn J H G Simons, Hendrik Koffijberg, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 16, 2022
Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer
Martijn J H G Simons, Carin A Uyl-de Groot, Valesca P Retèl, et al.
Pharmacoeconomics
|
January 9, 2024
Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy
Zakile A Mfumbilwa, Martijn J H G Simons, Bram Ramaekers, et al.
Scientific Reports
|
February 9, 2023
Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
Zakile A Mfumbilwa, Janneke A Wilschut, Martijn J H G Simons, et al.
Pharmacoeconomics
|
August 18, 2021
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
Martijn J H G Simons, Valesca P Retèl, Bram L T Ramaekers, et al.
Page
of 1